6.50
1.40%
0.09
After Hours:
6.50
Cytek Biosciences Inc stock is traded at $6.50, with a volume of 566.03K.
It is up +1.40% in the last 24 hours and up +38.59% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$6.41
Open:
$6.49
24h Volume:
566.03K
Relative Volume:
0.84
Market Cap:
$825.68M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-162.50
EPS:
-0.04
Net Cash Flow:
$454.00K
1W Performance:
+6.04%
1M Performance:
+38.59%
6M Performance:
+9.06%
1Y Performance:
-4.41%
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
6.50 | 825.68M | 193.01M | -12.15M | 454.00K | -0.04 |
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-14-23 | Initiated | Stephens | Overweight |
Jul-19-23 | Initiated | Raymond James | Mkt Perform |
Jan-06-22 | Resumed | Piper Sandler | Overweight |
Cytek Biosciences Inc Stock (CTKB) Latest News
Cytek Biosciences stock target cut, overweight on revised estimates - Investing.com
Cytek Biosciences stock target cut, overweight on revised estimates By Investing.com - Investing.com Canada
Cytek Biosciences, Inc. (NASDAQ:CTKB) Shares Bought by GSA Capital Partners LLP - Defense World
Principal Financial Group Inc. Purchases 23,028 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Brown Capital Management LLC Trims Stock Holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) - MarketBeat
Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Cytek Biosciences to Present at Piper Sandler Healthcare Conference 2024 | CTKB Stock News - StockTitan
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program - GlobeNewswire
Cytek Biosciences Crowned 2024 BioTech Company of the Year, Leading in Flow Cytometry | CTKB Stock News - StockTitan
Cytek Biosciences (NASDAQ:CTKB) Shares Gap DownShould You Sell? - MarketBeat
Learn to Evaluate (CTKB) using the Charts - Stock Traders Daily
Cytek Biosciences, Inc. (NASDAQ:CTKB) Sees Significant Decrease in Short Interest - MarketBeat
Brown Capital Management LLC Adjusts Stake in Cytek Biosciences Inc - GuruFocus.com
Piper Sandler Forecasts Strong Price Appreciation for Cytek Biosciences (NASDAQ:CTKB) Stock - Defense World
CTKBCytek Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
Cytek Biosciences Inc. (CTKB) Quarterly 10-Q Report - Quartzy
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter - GlobeNewswire
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Call Transcript - Insider Monkey
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump - Simply Wall St
Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Cytek Biosciences (NASDAQ:CTKB) Shares Up 26.7% After Strong Earnings - Defense World
Earnings call: Cytek Biosciences reports steady growth in Q3 2024 By Investing.com - Investing.com South Africa
Earnings call: Cytek Biosciences reports steady growth in Q3 2024 - Investing.com India
Cytek Biosciences (NASDAQ:CTKB) Shares Up 26.7% After Earnings Beat - MarketBeat
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Cytek Biosciences Inc (CTKB) Q3 2024 Earnings Call Highlights: Revenue Growth and Positive Net ... By GuruFocus - Investing.com Canada
Cytek Biosciences Reports Third Quarter 2024 Financial Results - GlobeNewswire
Cytek Biosciences’ Q3 2024 Financial Highlights - TipRanks
Cytek Biosciences, Inc. (CTKB) Q3 Earnings and Revenues Beat Estimates - MSN
Cytek Biosciences earnings matched, revenue topped estimates - Investing.com
Cytek Biosciences Inc (CTKB) Q3 2024 Earnings: Revenue Hits $51. - GuruFocus.com
Cytek Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Preview: Cytek Biosciences's Earnings - Benzinga
What To Expect From Cytek Biosciences Inc (CTKB) Q3 2024 Earnings - Yahoo Finance
November 2024's Top US Penny Stocks With Growth Potential - Simply Wall St
Cytek Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire
Cytek Biosciences (CTKB) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Cytek Biosciences to Report Third Quarter 2024 Financial Results on November 5, 2024 - GlobeNewswire
Cytek® Biosciences automates panel design with new intelligent algorithm - MSN
Layoff Tracker: Dublin-Based CRO With US Offices Signals Upcoming Layoffs - BioSpace
(CTKB) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases 2,460 Shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) - Defense World
Cytek Biosciences, Inc. (NASDAQ:CTKB) Short Interest Up 5.4% in September - MarketBeat
Institutional investors have a lot riding on Cytek Biosciences, Inc. (NASDAQ:CTKB) with 53% ownership - Simply Wall St
What technical indicators reveal about CTKB stock - US Post News
Cytek BioSciences Inc (CTKB) Becoming More Attractive for Investors - Knox Daily
Millennium Management LLC Raises Stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Shares Up 3.6%Still a Buy? - MarketBeat
Analysts review Cytek BioSciences Inc’s rating - Knox Daily
Examining Cytek BioSciences Inc (CTKB) more closely is necessary - US Post News
Quarterly Snapshot: Quick and Current Ratios for Cytek BioSciences Inc (CTKB) - The Dwinnex
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytek Biosciences Inc Stock (CTKB) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Yan Ming | CHIEF TECHNOLOGY OFFICER |
Apr 09 '24 |
Sale |
7.00 |
1,900 |
13,304 |
6,008,502 |
Yan Ming | CHIEF TECHNOLOGY OFFICER |
Mar 18 '24 |
Sale |
6.77 |
20,000 |
135,400 |
6,030,402 |
Yan Ming | CHIEF TECHNOLOGY OFFICER |
Mar 19 '24 |
Sale |
6.71 |
20,000 |
134,200 |
6,010,402 |
Jeanmonod Patrik | Chief Financial Officer |
Dec 26 '23 |
Sale |
9.50 |
3,000 |
28,500 |
93,400 |
Yan Ming | Chief Technology Officer |
Dec 19 '23 |
Sale |
9.43 |
20,000 |
188,600 |
6,042,103 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):